Botanical skin solutions company Kamedis revealed on Tuesday the receipt of US Patent and Trademark Office Notice of Allowance for the patent application for its Kamedis Calm Eczema Therapy Cream for the treatment of eczema-related inflammation and infection.

Under the US Patent and Trademark, the company will receive patent protection for Kamedis Calm Eczema Therapy Cream's proprietary combination of traditional Chinese botanicals. The Kamedis product line includes botanical-based treatment regimens for acne, dandruff and dry feet. The pending patent will be its first US patent.

The company said the Kamedis Calm Eczema Therapy Cream utilises an exclusive formulation of Chinese Rhubarb, Great Burnet, Tree of Heaven, Baikal Skullcap, Cnidium Fruit and Licorice extracts in conjunction with conventional active and inactive ingredients. Each botanical in the Kamedis formula contains multiple components that modulate different physiological mechanisms simultaneously, helping restore the natural barrier that protects skin against bacteria and irritants.

In conjunction, the company's Kamedis Calm Eczema Therapy Cream has been clinically proven to reduce eczema flare-ups by 50% in two weeks, providing significant relief for a condition that affects more than 31m people in the US including one-third of infants.

Additionally, a double-blind, randomised clinical trial is scheduled for completion in early 2019 to examine Kamedis Calm Eczema Therapy Cream's botanical ingredients role in the healing process. The trial is comparing the effectiveness of Kamedis Calm Eczema Therapy Cream, the Kamedis product without the Chinese botanical formulation and a competitive OTC brand in mitigating eczema symptoms among 108 US children and adults, concluded the company.